TNF and cancer: Only the analysis between tofacitinib and anti-TNF agents revealed a slightly increased overall risk of cancer in the tofacitinib groups (RR = 1.40 p = 0.02); this result was maintained when NMSC was excluded from the analysis (RR = 1.47; p = 0.03) and was lost in the analysis of NMSC alone (RR = 1.3; p = 0.88).